Chronic Kidney Disease – Stage 3: A Complete Patient Guide

Overview

Chronic kidney disease (CKD) is a progressive loss of kidney function that lasts for three months or longer. Stage 3 CKD is defined by a glomerular filtration rate (GFR) of **30–59 mL/min/1.73 m²**, indicating moderate reduction in kidney filtering capacity.

• Who it affects: Adults over 45 are most commonly diagnosed, but younger individuals with diabetes, hypertension, or a family history can also develop stage 3 CKD.
• Prevalence: In the United States, about **15 %** of adults have CKD; roughly one‑third of those are in stage 3 (CDC, 2023). Worldwide, >850 million people are estimated to have CKD, making it a leading cause of morbidity and health‑care cost (WHO, 2022).

Stage 3 is a pivotal point: with timely intervention, disease progression can be slowed and complications minimized.

Symptoms

Early CKD often has few or no symptoms, which is why routine testing is essential. When symptoms appear, they tend to be vague and overlap with other conditions.

General symptoms

• Fatigue or weakness – due to anemia and reduced erythropoietin production.
• Swelling (edema) – especially in the ankles, feet, or around the eyes, caused by fluid retention.
• Decreased appetite or nausea – metabolic waste buildup can affect the gastrointestinal tract.
• Sleep disturbances – restless legs, itching, or nocturia (waking to urinate).

Urinary changes

• More frequent urination, especially at night.
• Foamy or bubbly urine (proteinuria).
• Dark‑colored urine, sometimes with a “tea‑colored” hue.

Cardiovascular‑related symptoms

• Shortness of breath on exertion (fluid in lungs).
• Chest discomfort or palpitations due to electrolyte disturbances.

Other possible clues

• Itchy skin (uremic pruritus) from toxin accumulation.
• Metallic taste in the mouth.
• Muscle cramps, especially at night.

If any of these symptoms develop or worsen, discuss them promptly with your health‑care provider.

Causes and Risk Factors

CKD results from damage to the nephrons—tiny filtering units in the kidneys. The underlying cause determines the rate of progression.

Common causes

• Diabetes mellitus – high blood sugar damages glomeruli; accounts for ~45 % of CKD cases (NIH, 2023).
• Hypertension – high pressure injures blood vessels in the kidney.
• Glomerulonephritis – inflammation of the filtering units.
• Polycystic kidney disease – hereditary cyst formation.
• Obstructive uropathy – kidney stones, enlarged prostate, or tumors blocking urine flow.

Risk factors

• Age > 45 years.
• Family history of kidney disease.
• African American, Hispanic, or Native American ancestry (higher prevalence).
• Obesity (BMI ≥ 30 kg/m²).
• Cardiovascular disease, smoking, and high‑protein diets.
• Use of nephrotoxic medications (NSAIDs, certain antibiotics, contrast agents).

Identifying and modifying these risk factors is a cornerstone of slowing CKD progression.

Diagnosis

Diagnosis relies on laboratory measurements, imaging, and a careful medical history.

Key tests

• Serum creatinine & eGFR – estimated glomerular filtration rate is calculated from serum creatinine, age, sex, and race (CKD‑EPI equation). Stage 3 is confirmed when eGFR is 30–59 mL/min/1.73 m².
• Urine albumin‑to‑creatinine ratio (UACR) – detects proteinuria. Values ≥30 mg/g indicate kidney damage.
• Blood pressure measurement – hypertension is both a cause and consequence.
• Complete blood count (CBC) – assesses anemia.
• Serum electrolytes & bicarbonate – monitors potassium, phosphorus, and acid‑base balance.
• Imaging – renal ultrasound evaluates size, cysts, or obstruction.

Staging criteria (KDIGO 2023)

GFR (mL/min/1.73 m²)	Stage
≥90	1 (Normal‑high)
60‑89	2 (Mild reduction)
30‑59	3a (Moderate) / 3b (Moderate‑severe)
15‑29	4 (Severe)
<15	5 (Kidney failure)

Regular follow‑up labs (every 3–6 months) are recommended for stage 3 to monitor progression.

Treatment Options

Therapy aims to preserve kidney function, control complications, and improve quality of life.

Medications

• ACE inhibitors (e.g., lisinopril) or ARBs (e.g., losartan) – lower intraglomerular pressure and reduce proteinuria. Preferred first‑line for hypertension in CKD (KDIGO, 2023).
• Blood‑pressure agents – thiazide‑type diuretics, beta‑blockers, or calcium‑channel blockers if additional control is needed.
• Statins – indicated for adults >50 y with CKD to reduce cardiovascular risk (AHA/ACC 2022).
• Erythropoiesis‑stimulating agents (ESA) – treat anemia when hemoglobin <10 g/dL.
• Phosphate binders – lomitapide or calcium‑based binders if serum phosphorus rises >4.5 mg/dL.
• Vitamin D analogues – maintain calcium‑phosphate balance and suppress parathyroid hormone.

Lifestyle and non‑pharmacologic measures

• Blood‑pressure control – target <140/90 mmHg (or <130/80 mmHg if diabetic) per ACC/AHA 2022.
• Blood‑sugar management – aim for HbA1c ≈ 7 % (individualized).
• Dietary modifications – limit sodium (<2 g/day), moderate protein (0.8 g/kg/day), and control potassium/phosphorus according to labs.
• Smoking cessation – improves cardiovascular and renal outcomes.
• Regular exercise – 150 min/week of moderate activity unless contraindicated.

Procedures

Procedures are uncommon in stage 3 but may be needed for complications:

• Renal artery angioplasty for renovascular hypertension.
• Kidney biopsy when the cause is unclear.
• Referral for transplant evaluation if eGFR declines rapidly toward <20 mL/min/1.73 m².

Living with Chronic Kidney Disease, Stage 3

Adapting daily habits can make a big difference in slowing progression and feeling better.

Practical tips

• Medication adherence – use a pill organizer, set alarms, and keep a medication list.
• Fluid balance – most stage 3 patients can drink enough to stay hydrated, but restrict fluids only if a doctor advises.
• Monitor blood pressure at home – aim for the target range and bring logs to appointments.
• Check weight weekly – sudden gains may signal fluid retention.
• Dietary guidance – work with a renal dietitian; use portion‑size tools and read food labels for sodium and phosphorus additives.
• Foot care – diabetes and edema increase ulcer risk; inspect feet daily.
• Vaccinations – stay up‑to‑date on influenza, COVID‑19, pneumococcal, and hepatitis B vaccines (CDC, 2024).
• Support networks – join CKD support groups, either local or online, for emotional encouragement.

Monitoring schedule

Parameter	Frequency (Stage 3)
eGFR & serum creatinine	Every 3–6 months
UACR (proteinuria)	Every 6 months
Blood pressure	Weekly at home; every visit
HbA1c (if diabetic)	Every 3 months
Lipid panel	Annually

Prevention

While some risk factors (age, genetics) cannot be changed, many are modifiable.

• Control blood pressure – maintain <140/90 mmHg or lower.
• Manage diabetes – tight glucose control reduces CKD risk by ~30 % (UKPDS, 2021).
• Adopt a kidney‑friendly diet – DASH-style eating with reduced sodium and processed foods.
• Avoid nephrotoxic drugs – limit NSAIDs, check dose of contrast agents.
• Stay active – at least 30 minutes of walking most days.
• Weight management – aim for BMI 18.5–24.9 kg/m².
• Regular screening – B blood tests for at‑risk adults (diabetes, hypertension) annually.

Complications

If CKD is not adequately managed, a cascade of complications can arise:

• Progression to end‑stage renal disease (ESRD) – requiring dialysis or transplantation.
• Cardiovascular disease – CKD triples the risk of heart attack and stroke.
• Anemia – due to reduced erythropoietin.
• Bone‑mineral disorder – secondary hyperparathyroidism, vascular calcifications.
• Electrolyte abnormalities – hyperkalemia, metabolic acidosis.
• Fluid overload – peripheral edema, pulmonary congestion.
• Infections – impaired immune response.

When to Seek Emergency Care